[Potential Mechanisms and Research Advances of HDAC1 in Lung Cancer]

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Lung cancer has high incidence and mortality globally, with current treatments showing limited efficacy.
• Epigenetic modifications are implicated in tumor development, with histone deacetylase 1 (HDAC1) playing a key role.
• HDAC1 is frequently overexpressed in lung cancer, correlating with malignancy and poor patient outcomes.

Purpose of the Study:

• To review the role of HDAC1 in lung cancer pathogenesis and treatment resistance.
• To explore the therapeutic potential of HDAC1 inhibitors in lung cancer.
• To summarize the current research, development, and clinical status of HDAC1 inhibitors for precise lung cancer treatment.

Main Methods:

• Systematic review of literature on HDAC1 structure, function, and regulation in lung cancer.
• Analysis of HDAC1's association with lung cancer resistance to various therapies.
• Summary of research and clinical development of HDAC1 inhibitors.

Main Results:

• HDAC1 is a key epigenetic regulator involved in cell proliferation, differentiation, and apoptosis.
• High HDAC1 expression is linked to increased lung cancer malignancy, advanced stages, and poor prognosis.
• Aberrant HDAC1 activation contributes to resistance against chemotherapy, targeted therapy, and immunotherapy in lung cancer.

Conclusions:

• HDAC1 inhibitors represent a novel therapeutic avenue for lung cancer.
• Combining HDAC1 inhibitors with chemotherapy, targeted therapy, or immunotherapy can yield synergistic anti-tumor effects.
• Further research and clinical trials on HDAC1 inhibitors are crucial for advancing precise lung cancer treatment.